These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 38425247)

  • 1. Development and verification of a novel immunogenic cell death-related signature for predicting the prognosis and immune infiltration in triple-negative breast cancer.
    Li J; Li Z; Yang W; Pan J; You H; Yang L; Zhang X
    Cancer Rep (Hoboken); 2024 Mar; 7(3):e2007. PubMed ID: 38425247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel fatty-acid metabolism-based classification for triple negative breast cancer.
    Yang X; Tang W; He Y; An H; Wang J
    Aging (Albany NY); 2023 Feb; 15(4):1177-1198. PubMed ID: 36880837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of m6A modification patterns and development of m6A-hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer.
    Shen X; Zhong J; He J; Han J; Chen N
    Front Immunol; 2022; 13():978092. PubMed ID: 36105819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer.
    Zhang J; Zhang M; Tian Q; Yang J
    Clin Exp Med; 2023 Nov; 23(7):3867-3881. PubMed ID: 37219794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The molecular subtypes of triple negative breast cancer were defined and a ligand-receptor pair score model was constructed by comprehensive analysis of ligand-receptor pairs.
    Pan W; Song K; Zhang Y; Yang C; Zhang Y; Ji F; Zhang J; Shi J; Wang K
    Front Immunol; 2022; 13():982486. PubMed ID: 36119101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel immunogenic cell death-related genes signature for predicting prognosis, immune landscape and immunotherapy effect in hepatocellular carcinoma.
    Xu G; Jiang Y; Li Y; Ge J; Xu X; Chen D; Wu J
    J Cancer Res Clin Oncol; 2023 Dec; 149(18):16261-16277. PubMed ID: 37698679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
    Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
    Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer.
    Zheng J; Zhang YF; Han GH; Fan MY; Du MH; Zhang GC; Zhang B; Qiao J; Zhang SX; Cao JM
    Adv Ther; 2023 Jan; 40(1):310-330. PubMed ID: 36316558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.
    Huang P; Zhou X; Zheng M; Yu Y; Jin G; Zhang S
    Front Immunol; 2023; 14():1263537. PubMed ID: 37767092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Research and experimental verification on the mechanisms of cellular senescence in triple-negative breast cancer.
    Cao T; Huang M; Huang X; Tang T
    PeerJ; 2024; 12():e16935. PubMed ID: 38435998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic evaluation of tumor microenvironment and construction of a machine learning model to predict prognosis and immunotherapy efficacy in triple-negative breast cancer based on data mining and sequencing validation.
    Gou Q; Liu Z; Xie Y; Deng Y; Ma J; Li J; Zheng H
    Front Pharmacol; 2022; 13():995555. PubMed ID: 36225561
    [No Abstract]   [Full Text] [Related]  

  • 12. Natural killer cell-related prognostic risk model predicts prognosis and treatment outcomes in triple-negative breast cancer.
    Liu Z; Ding M; Qiu P; Pan K; Guo Q
    Front Immunol; 2023; 14():1200282. PubMed ID: 37520534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel molecular insights into pyroptosis in triple-negative breast cancer prognosis and immunotherapy.
    Yu B; Luo J; Yang Y; Zhen K; Shen B
    J Gene Med; 2024 Jan; 26(1):e3645. PubMed ID: 38041540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An immunogenic cell death-related classification predicts response to immunotherapy and prognosis in triple-negative breast cancer.
    Cheng XY; Liang Y; Zhang HF; Qian FZ; Sun XH; Liu XA
    Am J Transl Res; 2023; 15(4):2598-2609. PubMed ID: 37193173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization of immunogenic cell death indicates prognosis and tumor microenvironment infiltration in osteosarcoma.
    Liu Z; Liu B; Feng C; Li C; Wang H; Zhang H; Liu P; Li Z; He S; Tu C
    Front Immunol; 2022; 13():1071636. PubMed ID: 36569869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Genes Associated with Prognosis and Immunotherapy Prediction in Triple-Negative Breast Cancer via M1/M2 Macrophage Ratio.
    Liu J; Deng Y; Liu Z; Li X; Zhang M; Yu X; Liu T; Chen K; Li Z
    Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512096
    [No Abstract]   [Full Text] [Related]  

  • 17. Identification of immunogenic cell death-related subtypes used for predicting survival and immunotherapy of endometrial carcinoma through a bioinformatics analysis.
    Liu Z; Luo Y; Su L; Hu X
    Medicine (Baltimore); 2023 Aug; 102(31):e34571. PubMed ID: 37543760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of an ubiquitin-proteasome system signature for predicting prognosis and providing therapeutic guidance for patients with triple-negative breast cancer.
    Chen X; Ren C; Zhou Z; Chen J; Fan X; Li X; Chen J; Zhu J
    J Gene Med; 2024 Jan; 26(1):e3584. PubMed ID: 37605934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.
    Cui Y; Li Y; Long S; Xu Y; Liu X; Sun Z; Sun Y; Hu J; Li X
    BMC Med Genomics; 2023 Aug; 16(1):184. PubMed ID: 37553698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An ICD-Associated DAMP Gene signature predicts survival and immunotherapy response of patients with lung adenocarcinoma.
    Wu Y; Li K; Liang S; Lou X; Li Y; Xu D; Wu Y; Wang Y; Cui W
    Respir Res; 2023 May; 24(1):142. PubMed ID: 37259066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.